Petros Pharmaceuticals Top Insiders
PTPIDelisted Stock | USD 0.03 0 13.35% |
Petros Pharmaceuticals employs about 18 people. The company is managed by 5 executives with a total tenure of roughly 42 years, averaging almost 8.0 years of service per executive, having 3.6 employees per reported executive. Assessment of Petros Pharmaceuticals' management performance can provide insight into the firm performance.
Fady MBA President President Officer |
Petros |
Petros Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2897) % which means that it has lost $0.2897 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7133) %, meaning that it created substantial loss on money invested by shareholders. Petros Pharmaceuticals' management efficiency ratios could be used to measure how well Petros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Petros Pharmaceuticals Workforce Comparison
Petros Pharmaceuticals is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 403. Petros Pharmaceuticals holds roughly 18.0 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.41) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.41. Petros Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Petros Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Petros Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Petros Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Petros Pharmaceuticals Notable Stakeholders
A Petros Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Petros Pharmaceuticals often face trade-offs trying to please all of them. Petros Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Petros Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Fady MBA | President Officer | Profile | |
Mitchell MBA | VP Officer | Profile | |
Keith Lavan | Advisor | Profile | |
John Shulman | Executive Board | Profile | |
Robert Weinstein | Interim Officer | Profile |
About Petros Pharmaceuticals Management Performance
The success or failure of an entity such as Petros Pharmaceuticals often depends on how effective the management is. Petros Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Petros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Petros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on mens health therapeutics. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.
Petros Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Petros Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Petros Pharmaceuticals within its industry.Petros Pharmaceuticals Manpower Efficiency
Return on Petros Pharmaceuticals Manpower
Revenue Per Employee | 284K | |
Revenue Per Executive | 1M | |
Net Loss Per Employee | 795.5K | |
Net Loss Per Executive | 2.9M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Petros Pink Sheet
If you are still planning to invest in Petros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Petros Pharmaceuticals' history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |